Stada has delivered a solid performance in 2022 that has seen the German generics giant’s financials lifted in particular by a consumer healthcare segment that has now become the largest of the firm’s three business segments.
Stada Boosted By Consumer And Specialty Growth
As Generics Business Also Delivers Solid Improvement In 2022
Stada has celebrated “growing faster than the markets in which it operates” after delivering a 2022 performance that saw the firm’s earnings lifted in particular by increases in its consumer healthcare and specialty segments.
More from Earnings
More from Business
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.